Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung Cancer

Phase 2 Active not recruiting 47 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of concurrent chemoradiotherapy with oral vinorelbine, and immune maintenance therapy in patients with unresectable stage III non-small cell lung cancer after neoadjuvant chemo-immunotherapy, with a view to providing an effective treatment regimen for these patients.

Timeline

Start: 2023-03-20
Primary completion: 2025-04-10
Completion: 2026-06-10

Publications

Lian X, Shayan G, Yang S, Liu W, Zhang T, Lv J, Wang W, Wang J, Wang X, Xiao Z, Zhou Z, Bi N, Deng L. Efficacy and safety of oral vinorelbine with concurrent radiotherapy in unresectable stage III non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a single-arm, phase 2 trial. J Natl Cancer Cent. 2025 Jul 21;5(6):593-599. doi: 10.1016/j.jncc.2025.06.004. eCollection 2025 Dec.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vinorelbine	Small molecule	30 mg/m2	Oral

Indications

No indication recorded.